The GR antagonist mifepristone (11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-[1-propynyl]-[11ß,17ß]-estra-4,9-dien-3-one) has been shown to improve glucose tolerance in patients with overt Cushing's syndrome [12]. This evidence concerns the gene NR3C1 and Cushing syndrome.